Friday, June 19, 2015 12:01:13 PM
Oops. My post 3847 did discuss our drugs and our company, but it was written in relation to our acquisition of BRLI, and as time passes, as new people come to our board, they will see the opening statement and may decide that it has no relevance to them and so not read the rest.
What I meant to be sticked was my 3857 post that skips the BRLI section and goes directly to the in depth coverage of our drugs and also the discussion of our stock. I thought that that would be more helpful, and also that it would pique peoples attention, and get them to read the entire post.
You can read my 3857 post and see if it would work better than the one you sticked (and by the way, Thanks for sticking it. Now I can officially say that I am stuck up.) If you think that it is a better post, can you remove it and replace it with my updated 3857 post? Or it could be that there is not that much difference.
Whatever you decide. Thanks again for making it a permanent post.
What I meant to be sticked was my 3857 post that skips the BRLI section and goes directly to the in depth coverage of our drugs and also the discussion of our stock. I thought that that would be more helpful, and also that it would pique peoples attention, and get them to read the entire post.
You can read my 3857 post and see if it would work better than the one you sticked (and by the way, Thanks for sticking it. Now I can officially say that I am stuck up.) If you think that it is a better post, can you remove it and replace it with my updated 3857 post? Or it could be that there is not that much difference.
Whatever you decide. Thanks again for making it a permanent post.
Recent OPK News
- OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:16:55 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 08:10:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 08:50:09 PM
- OPKO Health to Participate in the Jefferies Biotech on the Beach Summit • GlobeNewswire Inc. • 02/27/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:07:43 PM
- OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/26/2026 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2026 01:00:00 PM
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism • GlobeNewswire Inc. • 02/04/2026 01:00:00 PM
- OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:11:42 PM
- OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference • GlobeNewswire Inc. • 11/19/2025 09:05:00 PM
- NextPlat Reports Third Quarter 2025 Results • PR Newswire (US) • 11/13/2025 01:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/29/2025 08:12:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2025 08:11:05 PM
- OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 10/29/2025 08:05:00 PM
- OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications • GlobeNewswire Inc. • 10/29/2025 12:00:00 PM
- OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers • GlobeNewswire Inc. • 10/28/2025 12:00:00 PM
- OPKO Health to Report Third Quarter 2025 Financial Results on October 29 • GlobeNewswire Inc. • 10/22/2025 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2025 08:02:57 PM
- Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses • PR Newswire (US) • 09/15/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2025 08:12:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2025 08:07:20 PM
- OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 07/31/2025 08:05:00 PM
- OPKO Health to Report Second Quarter 2025 Financial Results on July 31 • GlobeNewswire Inc. • 07/24/2025 08:05:00 PM
